FORTUM INJECTION 2G/VIAL

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Active ingredient:

CEFTAZIDIME

Available from:

GLAXOSMITHKLINE PHARMACEUTICAL SDN. BHD.

INN (International Name):

CEFTAZIDIME

Units in package:

77ml mL; 77 ml mL

Manufactured by:

GlaxoSmithKline Manufacturing S.p.A

Summary of Product characteristics

FORTUM ™
Ceftazidime
QUALITATIVE AND QUANTITATIVE COMPOSITION
FORTUM injection contains 250 mg, 500 mg, 1 g, or 2 g of ceftazidime (as pentahydrate).
Ceftazidime pentahydrate is formulated in a mixture with sodium carbonate. When constituted,
this mixture provides a solution of ceftazidime sodium.
PHARMACEUTICAL FORM
Powder for injection/infusion
CLINICAL PARTICULARS
Indications
Treatment of single or multiple infections caused by susceptible organisms.
May be used alone as first choice drug before the results of sensitivity tests are available.
May be used in combination with an aminoglycoside or most other beta-lactam antibiotics.
May be used with an antibiotic against anaerobes when the presence of Bacteroides fragilis is
suspected.
Susceptibility to FORTUM will vary with geography and time and local susceptibility data
should be consulted where available (see Pharmacological properties, Pharmacodynamic
effects).
Indications include:
- severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients - infections in patients in intensive care, e.g. infected burns
- respiratory tract infections including lung infections in cystic fibrosis
- ear, nose and throat infections
- urinary tract infections
- skin and soft tissue infections
- gastrointestinal, biliary and abdominal infections
- bone and joint infections